Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.847
Abstract: Cobimetinib is a kinase inhibitor indicated for use in combination with vemurafenib for treatment of unresectable/metastatic melanoma with specific BRAF mutations. Cobimetinib is extensively metabolized in liver; thus, patients with hepatic impairment (HI) might have… read more here.
Keywords: normal hepatic; hepatic impairment; hepatic function; drug ... See more keywords
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-18-4180
Abstract: Purpose: To report the 5-year overall survival (OS) landmark and the long-term safety profile of vemurafenib plus cobimetinib (BRAF plus MEK inhibition, respectively) in the BRIM7 study. Patients and Methods: This phase Ib, dose-finding, and… read more here.
Keywords: vemurafenib cobimetinib; study; melanoma; year ... See more keywords
Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells
Sign Up to like & getrecommendations! Published in 2018 at "Cellular Physiology and Biochemistry"
DOI: 10.1159/000490022
Abstract: Background/Aims: Mutations in the Ras/Raf/MEK/ERK pathway are detected in 50% of colorectal cancer cases and play a crucial role in cancer development and progression. Cobimetinib is a MEK inhibitor approved for the treatment of advanced… read more here.
Keywords: colorectal cancer; expression; cancer cells; cancer ... See more keywords
Cobimetinib Sensitizes Cervical Cancer to Paclitaxel via Suppressing Paclitaxel-Induced ERK Activation
Sign Up to like & getrecommendations! Published in 2022 at "Pharmacology"
DOI: 10.1159/000524305
Abstract: Introduction: Chemoresistance remains the main cause of treatment failure in cervical cancer and novel therapeutic strategies are required. Cobimetinib, a potent yet selective inhibitor of MEK1 and 2, is currently used to treat melanoma clinically.… read more here.
Keywords: cervical cancer; cobimetinib; erk activation; combination ... See more keywords
Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival.
Sign Up to like & getrecommendations! Published in 2019 at "Future oncology"
DOI: 10.2217/fon-2018-0659
Abstract: Approximately 50% of cutaneous melanomas harbor activating mutations of the BRAF-oncogene, making BRAF inhibitors (BRAFi) the standard treatment for this disease. However, disease responses are limited in duration mainly due to acquired resistance. Dual MAPK pathway… read more here.
Keywords: long term; melanoma mek; malignant melanoma; cobimetinib malignant ... See more keywords
Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1022496
Abstract: Background Preclinical and translational evidence suggest BRAF/MEK inhibitors modulate the tumor microenvironment (TME), providing rationale for combination with immunotherapy. Methods This investigator-initiated, phase I trial evaluated pembrolizumab, vemurafenib, and cobimetinib in patients with untreated, BRAFV600E/K… read more here.
Keywords: cobimetinib; phase trial; response; pembrolizumab ... See more keywords
The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Cancers"
DOI: 10.3390/cancers10060170
Abstract: The tumor suppressor protein p53 is inactivated in a large variety of cancer cells. Cellular p53 inhibitors like the mouse double minute 2 homolog (MDM2) commonly suppress the p53 function in acute myeloid leukemia (AML).… read more here.
Keywords: inhibitor; mdm2; treatment; aml ... See more keywords